Research highlights in nmCRPC: PROSPER and SPARTAN studies

Research highlights in nmCRPC: PROSPER and SPARTAN studies

VJOncology

1 year
459 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-resistant prostate cancer. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Armstrong points to limitations with current therapy, and how research into osteomimicry can help develop treatments that aim to cure bone metastases in these patients, rather than merely delaying the symptoms.
Up Next Autoplay
BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
Category: Acute Lymphoblastic Leukemia
0 Views
VJOncology 1 year
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Category: General
820 Views
VJOncology 1 year
Patient symptom and experience trackers
Patient symptom and experience trackers
Category: General
587 Views
VJOncology 1 year
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
Category: General
581 Views
VJOncology 1 year
The switch to biosimilar rituximab at UCH: 12 months on
The switch to biosimilar rituximab at UCH: 12 months on
Category: Lymphoma
562 Views
VJOncology 1 year
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Category: General
368 Views
VJOncology 1 year
Visibility of Oncology Pharmacists to patients
Visibility of Oncology Pharmacists to patients
Category: Other
263 Views
VJOncology 1 year
Smart app to allow patients to manage their side effects independently
Smart app to allow patients to manage their side effects independently
Category: Breast Cancer
80 Views
VJOncology 1 year
cancer-druginteractions.org: a comprehensive tool for HCPs
cancer-druginteractions.org: a comprehensive tool for HCPs
Category: Other
39 Views
VJOncology 1 year
The emergence of mixed speciality oncology
The emergence of mixed speciality oncology
Category: Other
67 Views
VJOncology 1 year